Process Validation

Validation of the manufacturing process is the ultimate goal of any validation policy

The fundamental GMP requirement for demonstrating adequate process control and the ability to manufacture reproducible product with the established quality.

Product Lifecycle

The concept of validation has evolved significantly over the past 20 years.

Process validation should be understood, beyond the traditional ‘three consecutive batches’, as the documented evidence of a solid scientific knowledge and understanding of the process, considering the critical parameters of the process and how these affect the quality attributes, the risks on the product and the process and the control mechanisms established for their prevention throughout their Lifecycle.

Three Stages of the Product Lifecycle

1. Products and Process Development

2. Validation of the Manufacturing Process

3. Keeping the Process in a Controlled State

Quality by Design (QbD) Approach

Product Lifecycle

Products developed under a Quality by Design (QbD) approach, where the control strategy for the process can be scientifically and comprehensively defined, continuous manufacturing can be used and and then, continuous process verification can replace the traditional validation approach.

Ongoing Process Verification

From the FDA’s ‘Risk-based approach’ initiative in 2002 to the present day and with the entry into force of new FDA guidelines (2011), EMA (2014) and the update of EU GMP Annex 15, there have been significant changes in the validation of manufacturing processes. 

In fact, the “three-stages” approach, highlighting the incorporation of the ongoing process verification (EU) or continued process verification (FDA) stage and the relevance given to the statistical processing of process and product data, are dramatically changing methodologies and approaches to address this essential requirement of GMP.

The main objective becomes to continuously ensure that the process remains in an adequate state of control during commercial batch manufacturing, as well as to facilitate the identification of necessary changes in the control strategy to drive continuous product and process improvement. 

To this end, a program for the collection and analysis of process and product data and their continuous quality must be established.

Ongoing Process Verification

Implementation should be an activity integrated into the company’s quality system and facilitates the identification of areas for improvement

Rephine has extensive experience at the international level in Process Validation, supported by numerous projects and successful inspections of our customers by the European health authorities and the FDA (Pre-Approval/Regular Inspections), including among others:

  • Validation of manufacturing and packaging processes
  • Ongoing process verification
  • Validation of cleaning methods
  • Validation of sterilization processes

Related Resources

GMP Raising the bar Blog series Header image May 25 Blog

QRM in Supplier Qualification & GxP Audits

Supplier qualification is no longer one-size-fits-all. This blog explores how QRM can transform supplier audits into risk-based, efficient, and compliant oversight.
Read More
GMP Raising the bar Blog series Header image May 25 Blog

From Mock Inspection to Governance: Building a Roadmap

A mock inspection is more than a rehearsal — it’s a chance to transform gaps into governance. Explore how structured CAPA and QRM can build ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

Operationalizing ALCOA+ in Digital GxP Systems

As pharma moves to digital platforms, ALCOA+ must be operationalized across QMS, LIMS, and ERP systems. Discover strategies to safeguard compliance and data integrity.
Read More
Medical Device Guide

Manufacturing Process Validation for Medical Devices

This whitepaper explains how to plan and execute manufacturing process validation for medical devices under EU MDR & IVDR, aligned with ISO 13485 and ISO ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

The Future is Hybrid: Annex 11, Annex 22 & GxP Compliance

The EMA’s 2025 draft updates highlight a hybrid future for pharma. Learn how unified governance of documentation, systems, and AI strengthens GxP compliance.
Read More
GMP Raising the bar Blog series Header image May 25 Blog

Integrating AI into QMS: Annex 22 & GxP Compliance

As Annex 22 highlights AI in pharma, QMS integration takes centre stage. Explore governance, validation, and oversight strategies to achieve GxP compliance.
Read More
微信图片 20250804170004 40 Blog

Deviation Management and Digital Tools in Pharma – Rephine Insights from CMC China

How can pharmaceutical companies turn everyday quality challenges into opportunities for improvement? At CMC China 2025, Rephine Consultant Ivan Zhang explored how a strong quality ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan Case Study

Digital QMS Transformation for Biopharmaceutical CDMO

A leading biopharmaceutical CDMO partnered with Rephine to replace manual quality processes with a validated digital QMS, improving efficiency and compliance. Learn how the two-phase ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

Validating AI Models in Pharma: Annex 22 & GxP Compliance

As AI integrates into pharma manufacturing, Annex 22 sets new expectations for validation. Learn how to ensure reliable models with strong data, oversight, and compliance.
Read More

Let's get in touch

Please get in touch. Our expert GMP audit team is only a click away, on standby to answer all your questions.
Social: Linkedin

REPHINE HQ

REPHINE BARCELONA S.L.U

  • Barcelona, Spain                               
  • +34 934 178065

REPHINE CHINA

  • Shanghai, China 

REPHINE INDIA

  • Hyderabad, India                               

Contact Us